Do analysts prefer CGTX or NLTX?

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 236.70%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cognition Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, CGTX or NLTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.24 N/A Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is CGTX or NLTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% Neoleukin Therapeutics N/A -37.22% -30.91%

Does the media favor AKBA or CGTX?

In the previous week, Akebia Therapeutics had 2 more articles in the media than Cognition Therapeutics. MarketBeat recorded 5 mentions for Akebia Therapeutics and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.67 beat Akebia Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SNDL or CGTX?

In the previous week, SNDL had 10 more articles in the media than Cognition Therapeutics. MarketBeat recorded 13 mentions for SNDL and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.67 beat SNDL's score of 0.08 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SNDL 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CGTX or LYEL?

In the previous week, Cognition Therapeutics had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for Cognition Therapeutics and 1 mentions for Lyell Immunopharma. Cognition Therapeutics' average media sentiment score of 0.67 beat Lyell Immunopharma's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CGTX or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% Zentalis Pharmaceuticals N/A -53.61% -40.67%

Does the media refer more to CGTX or ZNTL?

In the previous week, Cognition Therapeutics had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Cognition Therapeutics and 2 mentions for Zentalis Pharmaceuticals. Cognition Therapeutics' average media sentiment score of 0.67 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cognition Therapeutics (CGTX) Competitors

$0.99 +0.10 (+11.05%)

Closing price 03:59 PM Eastern

Extended Trading

$1.01 +0.02 (+1.92%)

As of 05:08 PM Eastern

Compare

CGTX vs. NLTX, AKBA, SNDL, LYEL, and ZNTL

Should you buy Cognition Therapeutics stock or one of its competitors? MarketBeat compares Cognition Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cognition Therapeutics include Neoleukin Therapeutics (NLTX), Akebia Therapeutics (AKBA), SNDL (SNDL), Lyell Immunopharma (LYEL), and Zentalis Pharmaceuticals (ZNTL).

How does Cognition Therapeutics compare to Neoleukin Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Cognition Therapeutics had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Cognition Therapeutics and 0 mentions for Neoleukin Therapeutics. Cognition Therapeutics' average media sentiment score of 0.67 beat Neoleukin Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
Neoleukin Therapeutics	Neutral

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Neoleukin Therapeutics' return on equity of -37.22% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Cognition Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Cognition Therapeutics presently has a consensus price target of $3.33, indicating a potential upside of 236.70%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cognition Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cognition Therapeutics beats Neoleukin Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Cognition Therapeutics compare to Akebia Therapeutics?

Akebia Therapeutics (NASDAQ:AKBA) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

In the previous week, Akebia Therapeutics had 2 more articles in the media than Cognition Therapeutics. MarketBeat recorded 5 mentions for Akebia Therapeutics and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.67 beat Akebia Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Akebia Therapeutics has higher revenue and earnings than Cognition Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.50	-$5.34M	-$0.08	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Cognition Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Akebia Therapeutics currently has a consensus price target of $4.67, indicating a potential upside of 252.20%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 236.70%. Given Akebia Therapeutics' higher possible upside, research analysts clearly believe Akebia Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Akebia Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Akebia Therapeutics and Cognition Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to SNDL?

SNDL (NASDAQ:SNDL) and Cognition Therapeutics (NASDAQ:CGTX) are related small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

SNDL has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market.

Cognition Therapeutics has a net margin of 0.00% compared to SNDL's net margin of -2.36%. SNDL's return on equity of -2.01% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-2.36%	-2.01%	-1.67%
Cognition Therapeutics	N/A	-72.68%	-53.07%

In the previous week, SNDL had 10 more articles in the media than Cognition Therapeutics. MarketBeat recorded 13 mentions for SNDL and 3 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.67 beat SNDL's score of 0.08 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SNDL	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SNDL has higher revenue and earnings than Cognition Therapeutics. SNDL is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$677.32M	0.46	-$11.29M	-$0.06	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

SNDL presently has a consensus price target of $5.00, suggesting a potential upside of 313.22%. Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 236.70%. Given SNDL's higher possible upside, equities analysts clearly believe SNDL is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cognition Therapeutics beats SNDL on 8 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Lyell Immunopharma?

Cognition Therapeutics (NASDAQ:CGTX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Cognition Therapeutics has higher earnings, but lower revenue than Lyell Immunopharma. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Lyell Immunopharma	$40K	8,348.38	-$274.45M	-$13.80	N/A

Cognition Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

Cognition Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Cognition Therapeutics' return on equity of -72.68% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

In the previous week, Cognition Therapeutics had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for Cognition Therapeutics and 1 mentions for Lyell Immunopharma. Cognition Therapeutics' average media sentiment score of 0.67 beat Lyell Immunopharma's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cognition Therapeutics currently has a consensus target price of $3.33, suggesting a potential upside of 236.70%. Lyell Immunopharma has a consensus target price of $43.20, suggesting a potential upside of 216.95%. Given Cognition Therapeutics' higher probable upside, research analysts clearly believe Cognition Therapeutics is more favorable than Lyell Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cognition Therapeutics beats Lyell Immunopharma on 10 of the 16 factors compared between the two stocks.

How does Cognition Therapeutics compare to Zentalis Pharmaceuticals?

Cognition Therapeutics (NASDAQ:CGTX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Zentalis Pharmaceuticals' return on equity of -53.61% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

Cognition Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

In the previous week, Cognition Therapeutics had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Cognition Therapeutics and 2 mentions for Zentalis Pharmaceuticals. Cognition Therapeutics' average media sentiment score of 0.67 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

43.4% of Cognition Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cognition Therapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Zentalis Pharmaceuticals	$67.43M	5.15	-$137.06M	-$1.73	N/A

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 236.70%. Zentalis Pharmaceuticals has a consensus price target of $6.75, suggesting a potential upside of 38.32%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Cognition Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Cognition Therapeutics beats Zentalis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGTX vs. The Competition

Export

Metric	Cognition Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$88.61M	$11.46B	$6.80B	$13.02B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-4.13	791.61	279.72	25.54
Price / Sales	N/A	947.20	648.71	115.96
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	2.54	10.44	11.12	6.36
Net Income	-$23.49M	$2.81B	$3.48B	$347.58M
7 Day Performance	7.20%	1.83%	2.59%	3.17%
1 Month Performance	-15.38%	-3.14%	-2.79%	-2.06%
1 Year Performance	38.69%	154.81%	64.29%	21.19%

Cognition Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGTX Cognition Therapeutics	2.1239 of 5 stars	$0.99 +11.0%	$3.33 +236.7%	+33.6%	$88.61M	N/A	N/A	20	News Coverage Upcoming Earnings
NLTX Neoleukin Therapeutics	N/A	$34.90 -1.9%	N/A	+51.0%	$327.99M	N/A	N/A	90	High Trading Volume
AKBA Akebia Therapeutics	1.9863 of 5 stars	$1.22 flat	$4.67 +282.5%	-64.8%	$327.27M	$236.20M	N/A	430	News Coverage Positive News Upcoming Earnings
SNDL SNDL	2.8571 of 5 stars	$1.25 -0.4%	$5.00 +301.6%	-25.8%	$320.46M	$677.32M	N/A	2,751	Earnings Report Analyst Downgrade
LYEL Lyell Immunopharma	2.6081 of 5 stars	$12.63 -1.2%	$43.20 +242.0%	+16.8%	$309.49M	$40K	N/A	270	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGTX) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cognition Therapeutics (CGTX) Competitors

CGTX vs. NLTX, AKBA, SNDL, LYEL, and ZNTL

How does Cognition Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Cognition Therapeutics compare to Akebia Therapeutics?

Summary

How does Cognition Therapeutics compare to SNDL?

Summary

How does Cognition Therapeutics compare to Lyell Immunopharma?

Summary

How does Cognition Therapeutics compare to Zentalis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cognition Therapeutics (CGTX) Competitors

CGTX vs. NLTX, AKBA, SNDL, LYEL, and ZNTL

How does Cognition Therapeutics compare to Neoleukin Therapeutics?

Does the media refer more to CGTX or NLTX?

Do insiders & institutionals believe in CGTX or NLTX?

Which has better valuation & earnings, CGTX or NLTX?

Is CGTX or NLTX more profitable?

Which has more risk and volatility, CGTX or NLTX?

Do analysts prefer CGTX or NLTX?

Summary

How does Cognition Therapeutics compare to Akebia Therapeutics?

Does the media favor AKBA or CGTX?

Which has higher valuation & earnings, AKBA or CGTX?

Is AKBA or CGTX more profitable?

Do analysts prefer AKBA or CGTX?

Which has more risk and volatility, AKBA or CGTX?

Do insiders & institutionals have more ownership in AKBA or CGTX?

Summary

How does Cognition Therapeutics compare to SNDL?

Do insiders & institutionals hold more shares of SNDL or CGTX?

Which has more risk & volatility, SNDL or CGTX?

Is SNDL or CGTX more profitable?

Does the media favor SNDL or CGTX?

Which has higher earnings & valuation, SNDL or CGTX?

Do analysts rate SNDL or CGTX?

Summary

How does Cognition Therapeutics compare to Lyell Immunopharma?

Which has preferable earnings & valuation, CGTX or LYEL?

Which has more volatility and risk, CGTX or LYEL?

Is CGTX or LYEL more profitable?

Does the media refer more to CGTX or LYEL?

Do analysts rate CGTX or LYEL?

Do insiders and institutionals hold more shares of CGTX or LYEL?

Summary

How does Cognition Therapeutics compare to Zentalis Pharmaceuticals?

Is CGTX or ZNTL more profitable?

Which has more risk and volatility, CGTX or ZNTL?

Does the media refer more to CGTX or ZNTL?

Do insiders & institutionals have more ownership in CGTX or ZNTL?

Which has preferable earnings and valuation, CGTX or ZNTL?

Do analysts prefer CGTX or ZNTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools